Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug

Lei Lei Wu

News Reporter

In April, Bristol Myers Squibb won approval for mavacamten, now marketed as Camzyos, to improve symptoms of obstructive hypertrophic cardiomyopathy (oHCM), a condition in which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bris­tol My­ers lines up a date with the FDA to ex­pand the foot­print of its $13B heart drug

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug